Format

Send to

Choose Destination
Urology. 2017 Jun;104:150-159. doi: 10.1016/j.urology.2016.12.033. Epub 2017 Mar 14.

The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).

Author information

1
University of Colorado, Denver, CO. Electronic address: edc@edavidcrawford.com.
2
Yale University, New Haven, CT.
3
Carolina Urologic Research Center, Myrtle Beach, SC.
4
Centre Hospitalier de L'Universite de Montreal, Montreal, QC, Canada.
5
Memorial Sloan Kettering Cancer Center, New York, NY.
6
Comprehensive Cancer Centers of Nevada, Las Vegas, NV.
7
Medical University of South Carolina, Charleston, SC.
8
Banner MD Anderson Cancer Center, Gilbert, AZ.
9
Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
10
Queen's University Belfast, Belfast, Northern Ireland, UK.
11
Université Catholique de Louvain, Brussels, Belgium.
12
Comprehensive Prostate Center, Nashville, TN.
13
Lancaster Urology, Lancaster, PA.
14
Icahn School of Medicine at Mount Sinai, New York, NY.
15
NRG Immunotherapy and Immunomodulation Committee, Scottsdale, AZ.
16
University of Washington, Seattle, WA.

Abstract

OBJECTIVE:

To offer recommendations on identification of disease progression, treatment management strategies, and suggestions on timing of initiating and discontinuing specific castration-resistant prostate cancer (CRPC) treatments.

MATERIALS AND METHODS:

The Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II Working Group convened to provide guidance on sequencing, combination, or layering of approved treatments for metastatic CRPC based on available data and clinical experience.

RESULTS:

A consensus was developed to address important questions on management of patients with metastatic CRPC.

CONCLUSION:

In the absence of large-scale clinical trials, the Working Group recommends that patients may best be managed with a layered approach of approved therapies with unique or complimentary mechanisms of action.

PMID:
28302580
DOI:
10.1016/j.urology.2016.12.033
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center